PURPOSE: The USA has a well-established network of central cancer registries (CCRs) that collect data using standardized definitions and protocols to provide population-based estimates of cancer incidence. The addition of cervical cancer precursors in select CCR operations would facilitate future studies measuring the population-level impact of human papillomavirus (HPV) vaccine. To assess the feasibility of collecting data on cervical cancer precursors, we conducted a multi-site surveillance study in three state-wide CCRs, to obtain annual case counts and compare rates of precursor lesions to those for invasive cervical cancer. METHODS: We developed standardized methods for case identification, data collection and transmission, training and quality assurance, while allowing for registry-specific strategies to accomplish surveillance objectives. We then conducted population-based surveillance for precancerous cervical lesions in three states using the protocols. RESULTS: We identified 5,718 cases of cervical cancer precursors during 2009. Age-adjusted incidence of cervical cancer precursors was 77 (Kentucky), 60 (Michigan), and 54 (Louisiana) per 100,000 women. Highest rates were observed in those aged 20-29 years: 274 (Kentucky), 202 (Michigan), and 196 (Louisiana) per 100,000. The variable with the most missing data was race/ethnicity, which was missing for 13 % of cases in Kentucky, 18 % in Michigan, and 1 % in Louisiana. Overall rates of cervical cancer precursors were over sixfold higher than invasive cervical cancer rates [rate ratios: 8.6 (Kentucky), 8.3 (Michigan), and 6.2 (Louisiana)]. CONCLUSIONS: Incorporating surveillance of cervical cancer precursors using existing CCR infrastructure is feasible and results in collection of population-based incidence data. Standardized collection of these data in high-quality registry systems will be useful in future activities monitoring the impact of HPV vaccination across states. As a result of this study, ongoing surveillance of these lesions has now been conducted in four CCRs since 2010.
PURPOSE: The USA has a well-established network of central cancer registries (CCRs) that collect data using standardized definitions and protocols to provide population-based estimates of cancer incidence. The addition of cervical cancer precursors in select CCR operations would facilitate future studies measuring the population-level impact of human papillomavirus (HPV) vaccine. To assess the feasibility of collecting data on cervical cancer precursors, we conducted a multi-site surveillance study in three state-wide CCRs, to obtain annual case counts and compare rates of precursor lesions to those for invasive cervical cancer. METHODS: We developed standardized methods for case identification, data collection and transmission, training and quality assurance, while allowing for registry-specific strategies to accomplish surveillance objectives. We then conducted population-based surveillance for precancerous cervical lesions in three states using the protocols. RESULTS: We identified 5,718 cases of cervical cancer precursors during 2009. Age-adjusted incidence of cervical cancer precursors was 77 (Kentucky), 60 (Michigan), and 54 (Louisiana) per 100,000 women. Highest rates were observed in those aged 20-29 years: 274 (Kentucky), 202 (Michigan), and 196 (Louisiana) per 100,000. The variable with the most missing data was race/ethnicity, which was missing for 13 % of cases in Kentucky, 18 % in Michigan, and 1 % in Louisiana. Overall rates of cervical cancer precursors were over sixfold higher than invasive cervical cancer rates [rate ratios: 8.6 (Kentucky), 8.3 (Michigan), and 6.2 (Louisiana)]. CONCLUSIONS: Incorporating surveillance of cervical cancer precursors using existing CCR infrastructure is feasible and results in collection of population-based incidence data. Standardized collection of these data in high-quality registry systems will be useful in future activities monitoring the impact of HPV vaccination across states. As a result of this study, ongoing surveillance of these lesions has now been conducted in four CCRs since 2010.
Authors: Cosette M Wheeler; William C Hunt; Jack Cuzick; Erika Langsfeld; Amanda Pearse; George D Montoya; Michael Robertson; Catherine A Shearman; Philip E Castle Journal: Int J Cancer Date: 2012-06-20 Impact factor: 7.396
Authors: Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers Journal: CA Cancer J Clin Date: 2012-03-14 Impact factor: 508.702
Authors: Teresa M Darragh; Terence J Colgan; J Thomas Cox; Debra S Heller; Michael R Henry; Ronald D Luff; Timothy McCalmont; Ritu Nayar; Joel M Palefsky; Mark H Stoler; Edward J Wilkinson; Richard J Zaino; David C Wilbur Journal: J Low Genit Tract Dis Date: 2012-07 Impact factor: 1.925
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Herschel W Lawson; Harrell Chesson; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2007-03-23
Authors: Martin Steinau; Elizabeth R Unger; Brenda Y Hernandez; Marc T Goodman; Glenn Copeland; Claudia Hopenhayn; Wendy Cozen; Maria S Saber; Youjie Huang; Edward S Peters; Charles F Lynch; Edward J Wilkinson; Mangalathu S Rajeevan; Christopher Lyu; Mona Saraiya Journal: J Low Genit Tract Dis Date: 2013-10 Impact factor: 1.925
Authors: Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg Journal: Lancet Oncol Date: 2008-04-11 Impact factor: 41.316
Authors: Indra Neil Sarkar; Elizabeth S Chen; Paul T Rosenau; Matthew B Storer; Beth Anderson; Jeffrey D Horbar Journal: AMIA Annu Symp Proc Date: 2014-11-14
Authors: Mei-Chin Hsieh; Elizabeth Van Dyne; Christina Lefante; Jean A Shapiro; Paran Pordell; Mary Anne Lynch; Natalie Gomez; Brent Mumphrey; Lauren Maniscalco; Rachna Jetly-Shridhar; Mona Saraiya; Xiao-Cheng Wu Journal: J Registry Manag Date: 2019
Authors: Meg Watson; Ashwini Soman; Elaine W Flagg; Elizabeth Unger; Dennis Deapen; Vivien W Chen; Lauren C Peres; Glenn Copeland; Thomas C Tucker; Erin Garnett; Mona Saraiya Journal: Prev Med Date: 2017-07-29 Impact factor: 4.018
Authors: Angela A Cleveland; Julia W Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Kayla Saadeh; Manideepthi Pemmaraju; Kyle Higgins; Sara Ehlers; Mary Scahill; Michelle L Johnson Jones; Troy Querec; Lauri E Markowitz; Elizabeth R Unger Journal: Int J Cancer Date: 2019-05-06 Impact factor: 7.316
Authors: Temitope E Filade; Eileen O Dareng; Toyosi Olawande; Tolani A Fagbohun; Amos O Adebayo; Clement A Adebamowo Journal: Front Public Health Date: 2017-09-06
Authors: Vicki B Benard; Philip E Castle; Steven A Jenison; William C Hunt; Jane J Kim; Jack Cuzick; Ji-Hyun Lee; Ruofei Du; Michael Robertson; Scott Norville; Cosette M Wheeler Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777